Lepu Medical Technology (SHE: 300003), a cardiovascular disease solutions provider, announced clinical approval from China’s National Medical Products Administration (NMPA) for MWX401, a small interfering RNA (siRNA) drug targeting primary hypertension. The approval enables Phase I/II clinical trials for the RNAi therapeutic, supported by strong preclinical data demonstrating sustained blood pressure reduction and superior efficacy vs. standard‑of‑care.
Regulatory Milestone
Item
Detail
Company
Lepu Medical Technology (SHE: 300003)
Product
MWX401
Drug Class
Small interfering RNA (siRNA)
Regulatory Action
NMPA clinical approval
Indication
Primary hypertension
Target
AGT (angiotensinogen) – key regulator of blood pressure
Marked AGT level reduction; significant BP lowering
Superior to valsartan
Dose‑Response
Good dose‑response relationship
—
Duration of Effect
≥ 12 weeks sustained BP reduction
—
Safety Profile
Good safety demonstrated
—
Strategic Implications
RNAi Cardiovascular Entry: MWX401 represents Lepu Medical’s expansion from devices (stents, valves) into RNA therapeutics, diversifying beyond interventional cardiology into pharmaceutical innovation.
AGT Target Validation: Targeting angiotensinogen (AGT)—the upstream precursor of angiotensin II—offers complete pathway suppression vs. ACE inhibitors or ARBs, potentially providing superior, longer‑lasting BP control.
Sustained Efficacy Advantage:12‑week duration from single subcutaneous dose suggests quarterly or less frequent dosing, dramatically improving patient compliance vs. daily oral antihypertensives.
Non‑Clinical Superiority:Superior to valsartan—a gold‑standard ARB—supports best‑in‑class potential and premium positioning in the $30 billion+ global hypertension market.
Market Context
Factor
Impact
Hypertension Market
~ $30 billion globally; dominated by generic ACE inhibitors, ARBs, and calcium channel blockers; innovation gap for resistant hypertension
RNAi vs. Small Molecule
siRNA offers durable, specific gene silencing with quarterly dosing; addresses adherence crisis in chronic cardiovascular disease management
AGT Competition
Alnylam’s zilebesiran (AGT siRNA) in Phase III; MWX401 positions Lepu as domestic China competitor with potential for differentiated profile
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I/II enrollment, AGT target engagement confirmation, and sustained BP reduction in humans. Actual results may differ due to risks including immunogenicity, off‑target effects, and competitive zilebesiran development timeline.-Fineline Info & Tech
By Fineline Cube